Sorbus Biomedical
Developer of a bench-top cell cultivation instrument that provides dynamic, body-like environmental control for in vitro cell and tissue culture. The company focuses on improving biological performance of lab-grown cells (including organoids), reducing operational resource consumption, and validating improved outcomes via independent benchmarking. It runs an early-access customer program and is pursuing seed-stage fundraising.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Cultivator Instrument (SCI)
A bench-top cell cultivation instrument engineered to provide dynamic, body-like environmental conditions for in vitro cell and tissue culture, aiming to improve cellular function and reduce resource consumption.
Cultivator Instrument (SCI)
A bench-top cell cultivation instrument engineered to provide dynamic, body-like environmental conditions for in vitro cell and tissue culture, aiming to improve cellular function and reduce resource consumption.
Services
Pilot deployment of the cultivation instrument with early customers for evaluation, feedback, and collaborative optimization.
Pilot deployment of the cultivation instrument with early customers for evaluation, feedback, and collaborative optimization.
Expertise Areas
- Cell culture technology
- Organoid cultivation and assay benchmarking
- Laboratory instrument development
- Physiological environment control for in vitro systems
Key Technologies
- Dynamic physiological environmental control systems for cell culture
- Organoid culture support platforms
- Bench-top automated cell cultivation instrumentation
- Gas-efficient environmental control and delivery
News & Updates
Company public notice that seed-stage investment is being raised in 2026.
Third-party comparative trials reported major and significant improvements in health and output of human lung cancer organoids relative to conventional incubators.
The instrument is referenced on the website as award-winning in the context of its technology communication.
Company public notice that seed-stage investment is being raised in 2026.
Third-party comparative trials reported major and significant improvements in health and output of human lung cancer organoids relative to conventional incubators.
The instrument is referenced on the website as award-winning in the context of its technology communication.